Inhibition of PLK1 activity by si-RNA or small molecule inhibitors demonstrates potent antitumor effects and synergizes with conventional chemotherapeutic agents in various pre-clinical models of cancer (Chapagai et al., 2025; Chiappa et al., 2022; Su et al., 2022; Zhao et al., 2025). Here, PLK1 is linked to cancer.